Item type |
琉球大学リポジトリ登録用アイテムタイプ(1) |
公開日 |
2023-07-07 |
タイトル |
|
|
タイトル |
Characteristics of discharge prescriptions for patients with schizophrenia or major depressive disorder: Real-world evidence from the Effectiveness of Guidelines for Dissemination and Education (EGUIDE) psychiatric treatment project |
|
言語 |
en |
作成者 |
Hashimoto, Naoki
Yasui-Furukori, Norio
Hasegawa, Naomi
Ishikawa, Shuhei
Numata, Shusuke
Hori, Hikaru
Iida, Hitoshi
Ichihashi, Kayo
Furihata, Ryuji
Murata, Atsunobu
Tsuboi, Takashi
Takeshima, Masahiro
Kyou, Yoshitaka
Komatsu, Hiroshi
Kubota, Chika
Ochi, Shinichiro
Takaesu, Yoshikazu
Usami, Masahide
Nagasawa, Tatsuya
Hishimoto, Akitoyo
Miura, Kenichiro
Matsumoto, Junya
Ohi, Kazutaka
Yamada, Hisashi
Inada, Ken
Watanabe, Koichiro
Shimoda, Kazutaka
Hashimoto, Ryota
|
アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
権利情報 |
|
|
言語 |
en |
|
権利情報 |
© 2021 The Author(s). Published by Elsevier B.V. |
権利情報 |
|
|
言語 |
en |
|
権利情報 |
This is an open access article under the CC BY-NC-ND license |
主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Antipsychotics |
主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Antidepressants |
主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Monopharmacy |
主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Polypharmacy |
主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
EGUIDE |
内容記述 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Background: Monopharmacy with antipsychotics and antidepressants is the first-line treatment for schizophrenia and major depressive disorder (MDD) in most clinical guidelines, while polypharmacy with psychotropic agents in the treatment of schizophrenia is common in clinical practice. There are no detailed data on the prescription patterns for inpatients with mental illness with reliable diagnoses made by treating psychiatrists. Methods: We gathered prescription data at discharge from 2177 patients with schizophrenia and 1238 patients with MDD from October 2016 to March 2018. Results: The patients with schizophrenia aged between 60 and 79 were prescribed lower doses of antipsychotics and hypnotics/anxiolytics than those aged between 40 and 59. There were significant differences between the prescription rate of antipsychotics in the patients with schizophrenia and that of antidepressants in the patients with MDD. The frequency of concomitant drugs such as anti-Parkinson drugs, anxiolytics/hypnotics and mood stabilizers in the subjects with schizophrenia prescribed antipsychotic polypharmacy was significantly higher than that with monotherapy. For the patients with schizophrenia, olanzapine, risperidone, aripiprazole, quetiapine, and blonanserin were the five most prescribed antipsychotics. For the patients with MDD, mirtazapine, duloxetine, escitalopram, trazodone and sertraline were the five most prescribed antidepressants. Conclusions: Our results showed the use of high doses of antipsychotics, high percentages of antipsychotic polypharmacy and concurrent use of hypnotics/anxiolytics in patients with schizophrenia. Notably, these data were collected before intensive instruction regarding the guidelines; therefore, we need to assess the change in the prescription pattern post guideline instruction. |
|
言語 |
en |
出版者 |
|
|
出版者 |
© 2021 The Author(s). Published by Elsevier B.V. |
|
言語 |
en |
言語 |
|
|
言語 |
eng |
資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
関連情報 |
|
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1016/j.ajp.2021.102744 |
収録物識別子 |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
1876-2026 |
収録物識別子 |
|
|
収録物識別子タイプ |
PISSN |
|
収録物識別子 |
1876-2018 |
収録物名 |
|
|
収録物名 |
Asian Journal of Psychiatry |
|
言語 |
en |
書誌情報 |
巻 63,
発行日 2021-09
|